Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect

This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic medullary thyroid cancer (MTC). Data on efficacy and safety are presented with the main focus on treatment-related hyperte...

Descripción completa

Detalles Bibliográficos
Autores principales: Højer Wang, Linnea, Wehland, Markus, Wise, Petra M., Infanger, Manfred, Grimm, Daniela, Kreissl, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917177/
https://www.ncbi.nlm.nih.gov/pubmed/36768635
http://dx.doi.org/10.3390/ijms24032312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917177/
https://www.ncbi.nlm.nih.gov/pubmed/36768635
http://dx.doi.org/10.3390/ijms24032312

Ejemplares similares